Fourth International Conference: Modern Vaccines/Adjuvants Formulation—Impact On Future Development

References

• Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011; 11:865 - 72; PMID: 22051890
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208:385 - 93; http://dx.doi.org/10.1093/infdis/jit192; PMID: 23785124
   PubMed Web of Science ®Google Scholar
• www.who.int.
   Google Scholar
• Andersen P, Doherty TM. The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005; 3:656 - 62; http://dx.doi.org/10.1038/nrmicro1211; PMID: 16012514
   PubMed Web of Science ®Google Scholar
• Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine 2010; 28:7897 - 906; http://dx.doi.org/10.1016/j.vaccine.2010.09.077; PMID: 20934457
   PubMed Web of Science ®Google Scholar
• Stano A, van der Vlies AJ, Martino MM, Swartz MA, Hubbell JA, Simeoni E. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 2011; 29:804 - 12; http://dx.doi.org/10.1016/j.vaccine.2010.11.010; PMID: 21094269
   PubMed Web of Science ®Google Scholar
• Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, Marsland BJ, et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A 2011; 108:E989 - 97; http://dx.doi.org/10.1073/pnas.1104264108; PMID: 21969597
   PubMed Web of Science ®Google Scholar
• Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, Pasquier M, et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011; 29:6959 - 66; http://dx.doi.org/10.1016/j.vaccine.2011.07.039; PMID: 21787826
   PubMed Web of Science ®Google Scholar
• Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. Journal of Biomaterials and Nanobiotechnology 2011; 2:626 - 39; http://dx.doi.org/10.4236/jbnb.2011.225075
   Google Scholar
• Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One 2008; 3:e2954; http://dx.doi.org/10.1371/journal.pone.0002954; PMID: 18698426
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr.. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008; 24:271 - 81; http://dx.doi.org/10.1089/aid.2007.0148; PMID: 18260780
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr.. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2008; 24:271 - 81; http://dx.doi.org/10.1089/aid.2007.0148; PMID: 18260780
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008; 15:348 - 58; http://dx.doi.org/10.1128/CVI.00440-07; PMID: 18057181
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007; 75:4020 - 9; http://dx.doi.org/10.1128/IAI.00070-07; PMID: 17502384
   PubMed Web of Science ®Google Scholar
• Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003; 21:3801 - 14; http://dx.doi.org/10.1016/S0264-410X(03)00381-5; PMID: 12922114
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Gerber M, Blanco LP, Makidon PE, Janczak KW, Beer M, et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010; 30:189 - 99; http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.60; PMID: 20370629
   PubMed Web of Science ®Google Scholar
• Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011; 6:e21823; http://dx.doi.org/10.1371/journal.pone.0021823; PMID: 21789184
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009; 27:4388 - 401; http://dx.doi.org/10.1016/j.vaccine.2009.05.032; PMID: 19450632
   PubMed Web of Science ®Google Scholar
• Reimer JM, Karlsson KH, Lövgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 2012; 7:e41451; http://dx.doi.org/10.1371/journal.pone.0041451; PMID: 22844480
   PubMed Web of Science ®Google Scholar
• Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013; 31:1725 - 33; http://dx.doi.org/10.1016/j.vaccine.2013.01.039; PMID: 23384754
   PubMed Web of Science ®Google Scholar
• Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049 - 59; http://dx.doi.org/10.1016/j.vaccine.2011.08.042; PMID: 21864624
   PubMed Web of Science ®Google Scholar
• Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158 - 66; http://dx.doi.org/10.1093/infdis/jis330; PMID: 22551811
   PubMed Web of Science ®Google Scholar